Giapreza Clinical Development Timeline
Executive Summary
Chronicle of the development and US FDA review of La Jolla Pharmaceutical's angiotensin II for increasing blood pressure in adults with septic or other distributive shock.
You may also be interested in...
Power Of Proprietary Drug Names To Be Studied By US FDA
FDA is worried about drug names that could appear to overstate efficacy and impact consumer and healthcare provider perceptions of the product.
Celgene, Agios Drug Enasidenib Among New Filings At EMA
Enasidenib, which last year became the first US-approved treatment for relapsed or refractory acute myeloid leukemia with an IDH2 mutation, is among a new crop of products being reviewed for marketing approval in the EU.
Lutathera Reviewers
US FDA staff who participated in the review and approval of AAA's treatment for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.